Dear Donna

I was pleased to be advised that NICE proposes to recommend the use of Degarelix as an option for advanced hormone-dependent prostate cancer, in men with spinal metastases, at risk of impending spinal cord compression. I believe that the Committee has taken account of the criteria as set out in the Appraisal consultation document and arrived at a decision based in a careful consideration of the available evidence.

I hope that this decision will confirmed at the Committee meeting on 11th February 2014, that the Final Appraisal Document will be published as soon as possible thereafter and the treatment made available at the earliest opportunity for the men who will benefit from its effects at a critical stage in the progress of their disease.

Best wishes

Stuart Watson

Patient Expert
(Nominated by Prostate Cancer UK)